Clinical Neurobiology of Serotonin and Addiction

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the relationship between 5-HT2R function, impulsivity and cue reactivity in cocaine dependent subjects and healthy controls and examine specific effects of escitalopram and mirtazapine on impulsivity and cue reactivity in human cocaine users.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

5HT2CR Balance in Brain Connectivity in Cocaine Dependence

NCT03921151

Cocaine Dependence

COMPLETED PHASE1/PHASE2

Brain Function and Structure in Cocaine Dependence

NCT02080832

Cocaine Dependence

COMPLETED PHASE2

Alterations in Serotonergic Functions in Cocaine Addicts - 1

NCT00000312

Cocaine-Related Disorders

COMPLETED PHASE1

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

NCT02537873

Cocaine Use Disorder

COMPLETED PHASE1

Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1

NCT00000309

Cocaine-Related Disorders

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Specific Aim 1: We will test the hypothesis that cocaine-dependent subjects will exhibit greater impulsivity than controls as determined by a battery of impulsivity measures and that impulsivity will be associated with specific profiles of 5-HT2AR and/or 5-HT2CR expression in platelets. We predict that treatment of cocaine-dependent subjects with escitalopram and/or mirtazapine will reduce impulsivity and cocaine-positive urines, in concert with a normalized balance of platelet 5-HT2AR and/or 5-HT2CR expression.

Specific Aim 2: We will test the hypothesis that cocaine-dependent subjects will exhibit greater cue reactivity than controls as determined by a modified Stroop task, and that cue reactivity will be associated with specific profiles of 5-HT2AR and/or 5-HT2CR expression in platelets. We predict that treatment of cocaine-dependent subjects with escitalopram and/or mirtazapine will reduce cue reactivity and cocaine-positive urines, in concert with a normalized balance of platelet 5-HT2AR and/or 5-HT2CR expression.

Specific Aim 3: We will test the hypothesis that specific polymorphisms in the 5-HT2AR and/or 5-HT2CR will predict baseline impulsivity and/or cue reactivity as well as treatment response to serotonergic medications in cocaine-dependent subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cocaine Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A (escitalopram)

Escitalopram

Group Type EXPERIMENTAL

Escitalopram

Intervention Type DRUG

Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28

B (placebo)

Placebo

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Once daily days 1-28

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28

Intervention Type DRUG

Placebo

Once daily days 1-28

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lexapro

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-Drug Abusing Control Subjects: Male and female subjects age 18 to 55 who do not meet current or past DSM-IV criteria for any Axis I disorder including substance abuse or dependence.
* Cocaine Dependent Subjects: Male and female subjects age 18 to 55 who meet current DSM-IV criteria for cocaine dependence.
* Female subjects: a negative pregnancy test.

Exclusion Criteria

* Non-Drug Abusing Control Subjects:

1. Current or past DSM-IV Axis I disorder
2. Any serious non-psychiatric medical illness requiring ongoing medical treatment or which could affect the central nervous system.
3. Positive HIV test.
4. For female subjects: a positive pregnancy test or breast feeding.
5. Concomitant use of prescription medications that could affect the central nervous system.
6. Active suicidal ideation.
7. Hamilton Depression or Anxiety Scale score greater than 15
* Cocaine Dependent Subjects:

1. Current DSM-IV Axis I disorder other than substance abuse/dependence
2. Current diagnosis of other substance dependence besides cocaine.
3. Any serious non-psychiatric medical illness requiring ongoing medical treatment or which could affect the central nervous system.
4. Positive HIV test.
5. For female subjects: a positive pregnancy test or breast feeding.
6. Concomitant use of prescription medications that could affect the central nervous system.
7. Active suicidal ideation.
8. Subjects within 14 days of discontinuing a monoamine oxidase inhibitor.
9. Subjects with cardiac arrythmias.
10. Subjects with known hypersensitivity to escitalopram or citalopram, or mirtazapine
11. Hamilton Depression or Anxiety Scale score greater than 15.
12. Current alcohol abuse or dependence.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes